Search

Your search keyword '"Nissen, N. I."' showing total 411 results
Start Over Author "Nissen, N. I."
411 results on '"Nissen, N. I."'

2. MON-PO597: The effect of a perioperative multinutrient supplement on collagen synthesis during early hernia repair: A randomised clinical pilot study

Author

Kjær, Marie, Frederiksen, A K S, Nissen, N I, Willumsen, Nicholas, van Hall, Gerrit, Jørgensen, Lars Nannestad, Andersen, Jens Rikardt, Ågren, Magnus S, Kjær, Marie, Frederiksen, A K S, Nissen, N I, Willumsen, Nicholas, van Hall, Gerrit, Jørgensen, Lars Nannestad, Andersen, Jens Rikardt, and Ågren, Magnus S

Abstract

Rationale: The inguinal hernia disease is associated with an imbalanced collagen metabolism including attenuated type V collagen synthesis. The aim of the present study was to normalise this distorted collagen equilibrium by supplying a combination of nutrients necessary for collagen synthesis to patients undergoing inguinal hernia repair. Methods: Twenty-one male patients scheduled for Lichtenstein inguinal hernia repair were randomized to an enriched nutritional supplementation (ENS-protein) group receiving 55 mg zinc, 1250 mg vitamin C, 14 g arginine and 14 g glutamine daily (n = 10) or to a control group (n = 11). Both groups received 1.5 g/kg of high-quality protein daily for 28 days. In addition, experimental epidermal wounds were created from raised suction blisters. Biomarkers of type I (CICP), type III (PRO-C3) and type V (PRO-C5) collagen synthesis were measured by enzyme-linked immunosorbent assays together with zinc and free amino acids in serum collected at baseline (day -14), day 0 before surgery and on postoperative day 1 (day 1). Wound fluids from surgical drain were analysed for CICP, PRO-C3 and PRO-C5 on postoperative days 1 and 2. Results: Fourteen days of ENS-protein raised the serum zinc level (p = 0.002) but reduced (p = 0.022) total amino acid levels preoperatively. Postoperatively, serum PRO-C5 decreased (p = 0.046) in the protein group but not in the patients receiving ENS-protein, who also had higher (p = 0.041) PRO-C5 levels than the protein group on day 1. CICP wound fluid levels increased from day 1 to day 2 in both groups and were higher on day 2 in the ENS-protein group compared with the protein group (P = 0.029). PRO-C3 increased (p = 0.028) from day 1–day 2 in the ENS-protein group, but not in the protein group. One patient in the ENS-protein group developed wound infection and subsequent hernia recurrence. In the protein group, two patients developed wound infections and hernia recurred in three other pa

Published
2019

3. Scientific Proceedings Second International Symposium on Cytostatic Drug Resistance

Author

Hill, Bridget T., Hosking, L. K., McClean, S., Shellard, S. A., Dempke, W. C. M., Whelan, R. D. H., Sehested, M., Friche, E., Demant, E. J. F., Jensen, P. B., Kopnin, B. P., Wolf, B., Seidel, A., Nickelsen, M., Brandt, I., Heinemann, G., Dietel, M., Bremer, S., Hoof, T., Tümmler, B., Broxterman, H. J., Versantvoort, C. H. M., Kuiper, C. M., Feller, N., Schuurhuis, G. J., Lankelma, J., Gupta, S., Tsuruo, T., Kim, C., Gollapudi, S., Bittl, A., Nap, M., Jäger, W., Lathan, B., Lang, N., Raikhlin, N. T., Perevozchikov, A. G., Volodina, J. L., Licht T., Fiebig H. H., Bross K. J., Herrmann F., Mertelsmann R., Bashir, I., Sikora, K., Foster, C. S., Castagna, M., Viacava, P., Cianfrigliao, M., Favati, A., Collecchi, P., Caligo, M. A., Cipollini, G., Bevilacqua, G., Schrenk, D., Gant, T. W., Silverman, J. A., Thorgeirsson, S. S., Harstrick, A., Zhang, Z. G., Schmoll, H. J., Rustum, Y., Mitze, M., Beck, T., Weikel, W., Brumm, C., Knapstein, P. G., McDonald, T., Gardner, P., Kang, N., van der Heyden, S. A. M., Elst, H. J., Stein, U., Jandrig, B., Krause, H., Schmidt-Peter, P., Frege, J., Wunderlich, V., Boven, E., van Kalken, C. K., Pinedo, H. M., Gebauer, W., Fallgren-Gebauer, E., Diete, M., Wagner, T., Müller, M. R., Lennartz, K., Nowrousian, H. R., Seeber, S., Shtil, A. A., Kazarov, A. R., Gudkov, A. V., Stavrovskaya, A. A., Djuraeva, F. H., Stromskaya, T. P., Noller, A., Frese, G., Neumann, M., Wilisch, A., Probst, H., Gekeler, V., Handgretinger, R., Schmidt, H., Muller, C. P., Dopfer, R., Klingebiel, T., Niethammer, D., Weger, S., Diddens, H., Daumiller, E., Bunge, A., Lilischkis, R., Salmassi, A., Kopun M., Scherthan H., Granzow C., Leuschner, I., Schmidt, D., Hoffmann, H., Harms, D., Scagliotli, G. V., Leonardo, E., Cappia, S., Esposito, G., Tombesi, M., Cianfriglia, M., Esposito, G. V., Merendino, N., Viora, M., Caserta, M., Tritarelli, E., Rocca, E., Boccoli, G., Samoggia, P., Fossati, C., Testa, U., Peschle, C., Darling, J. L., Ashmore, S. M., Peterson, D. C., Thomas, D. G. T., Kramer, R. A., Stanlunas, R., Summerhayes, T., Lion, T., Shoemaker, R. H., Wu, L., Smythe, A., Boyd, M. R., Beck, W. T., Danks, M. K., Wolverton, J. S., Chen, M., Bugg, B. Y., Suttle, D. P., Catapano, C. V., Fernandes, D. J., Gieseler, F., Boege, F., Erttmann, R., Arps, H., Zwelling, L., Wilms, K., Biersack, H., Kaspers, G. J. L., Pieters, R., Klumper, E., de Waal, F. C., van Wering, E. R., Veerman, A. J. P., Schmidt, C. A., Lorenz, F., Schäfer, A., Kirsch, A., Siegert, W., Huhn, D., Simon, W. E., Siebert, G., Schneider, M., Oettling, M., Reymann, A., Entmann, R., Schmidt, S., Woermann, C., Windmeier, C., Herzig, I., Schaefer, B., Heidebrecht, H. J., Wacker, H. H., Künnemann, H., van Heijningen, Th. H. M., Slovak, M. L., Baak, J. P. A., Steidtmann, K., Fichtinger-Schepman, A. -M. J., Hill, B. I., Scanlon, K. J., Zeller, W. J., Chen, G., Gietema, J. A., de Vries, E. G. E, Sleijfer, D.Th, Willemse, P. H. B., Guchelaar, H. J., Uges, D. R. A., Aulenbacher, P., Voegeli, R., Mulder, N. H., Skrezek, C., Bertermann, H., Eichholtz-Wirth, H., Born, R., Bier, H., Koch, M., Bernhardt, G., Hählen, K., Reile, H., van Zantwijk, C. H., Wering, E. R. van, Görögh, T., Lippert, B., Werner, J. A., Eickbohm, J. E., Mickiseh, G. H., Gottesman, M. M., Pastan, I., Hofmann, J., Wolf, A., Spitaler, M., Bock, G., Grunicke, H., Ponstingl, H., Roth, I., Granzow, C., Dörner, C., Erttmann, R., Looft, G., Ossenkoppele, G. J., Scheffer, G. L., Atassi, G., Pierre, A., Kraus, L., Leonce, S., Regnier, G., Dhainaut, A., Ponstingl H., Stöhr M., Rohlff, C., Glazer, R. I., Cho-Chung, Y. S., Höllt, V., Kouba, M., Vogt, G., Allmeier, H., Nissen, N. I., Cros, S., Guilbaud, N., Dunn, T., Berlion, M., Atassi, G., Bizzari, J. P., Messing, A. M., Matuschek, A., Mutter, I., Kiwit, J. C. W., Bastian, L., Goretzki, P. E., Frilling, A., Simon, D., Röher, H. D., Reichle, A., Altmayr, F., Rastetter, J., Erbil, C., Jaques, G., Maasberg, M., Havemann, K., Häußermann, K., Heidebrecht, H. -J., Van de Vrie, W., Gheuens, E. E. O., Durante, N. M. C., De Bruijn, E. A., Marquet, R. L., Van Oosterom, A. T., Eggermont, A. M. M., Stow, M. W., Vickers, S. E., Warr, J. R., Roller, E., Eichelbaum, M., Klumpp, B., Krause, J., Schumacher, K., Hörner, S., Laßmann, A., Traugott, U., Schlick, E., Bürkle, D., Futscher BW, List AF, Dalton WS, Ladda, E., Bühl, K., Weimer, A., Eser, C., Hamprecht, K., Schalk, K. P., Jackisch, C., Brandt, B., Blum, M., Louwen, F., Schulz, K., Hanker, J. P., Rüther, U., Schmidt, A., Müller, H. A. G., Nunnensiek, C., Bader, H., Eisenberger, F., Jipp, P., Niethammer, B., Muller, C., Ling, V., Joncourt, F., Redmond, S., Stöhr, M., Buser, K., Fey, M., Tobler, A., Brunner, K., Gratwohl, A., Cerrry, T., Nuessler, V., Pelka-Fleischer, R., Nerl, C., Beckert, B., Wilmanns, W., Hegewisch-Becker, S., Fliegner, M., Zander, A., Hossfeld, D. K., Blanz, J., Mewes, K., Ehninger, G., Zeller, K. -P., Schuldes, H., Herrmann, G., Boeckmann, W., Schroeder, R., Jonas, D., Zurborn, K. -H., Bruhn, H. D., Uharek, L., Glass, B., Gassmann, W., Loeffler, H., Mueller-Ruohholtz, W., Gassmann W., Glass B., Uharek L., Loeffler H., Mueller-Ruchholtz W., Jaquet, K., Kreipe, H., Felgner, J., Radzun, H. J., Parwaresch, M. R., Kogan EA, Mazurenko NN, Sekamova SM, Wolf, H., Röhe, K., Wilkens, K., Clausen, M., Henze, E., van der Bosch, J., Rüller, S., Schlaak, M., Köhl, U., Schwabe, D., Rohrbach, E., Montag, E., Bauer, S., Cinatl, J., Cinatl, Jr, I., Mainke, M., Geiss, H., Kornhuber, B., Juhl, H., Stritzel, H., Kalhoff, H., Schniegel, W., Menke, T., Pröbsting, B., Schulze-Westhoff, P., Boos, J., Weidner, J., Wedemeyer, N., Wiedorn, K., Ueda, Y., Blasius, S., Wuisman, P., Böcker, W., Roessner, A., Dockhorn-Dworniczak, B., Ramm, D., Knebel, J., Sass, W., Aufderheide, M., and Seifert, J.

Published
1991
Full Text
View/download PDF

6. The Epipodophyllotoxin Derivatives VM-26 and VP-16-213, 1976–1979, a Review

Author

Nissen, N. I., Dombernowsky, P., Hansen, H. H., Pedersen, A. G., Allfrey, V. G., editor, Allgöwer, M., editor, Berenblum, I., editor, Bergel, F., editor, Bernard, J., editor, Bernhard, W., editor, Blokhin, N. N., editor, Bock, H. E., editor, Braun, W., editor, Bucalossi, P., editor, Chaklin, A. V., editor, Chorazy, M., editor, Cunningham, G. J., editor, Della Porta, G., editor, Denoix, P., editor, Dulbecco, R., editor, Eagle, H., editor, Eker, R., editor, Good, R. A., editor, Grabar, P., editor, Harris, R. J. C., editor, Hecker, E., editor, Herbeuval, R., editor, Higginson, J., editor, Hueper, W. C., editor, Isliker, H., editor, Kieler, J., editor, Kirsten, W. H., editor, Klein, G., editor, Koprowski, H., editor, Koss, L. G., editor, Macbeth, R. A., editor, Martz, G., editor, Mathé, G., editor, Mühlbock, O., editor, Old, L. J., editor, Potter, V. R., editor, Sabin, A. B., editor, Sachs, L., editor, Saxén, E. A., editor, Schmidt, C. G., editor, Spiegelman, S., editor, Szybalski, W., editor, Tagnon, H., editor, Tissières, A., editor, Uehlinger, E., editor, Wissler, R. W., editor, Rentchnick, P., editor, Senn, H. J., editor, Mathé, Georges, editor, and Muggia, Franco M., editor

Published
1980
Full Text
View/download PDF

14. Hodgkin's Disease in Denmark: A National Clinical Study by the Danish Hodgkin Study Group, LYGRA

Author

Nordentoft, A. M., primary, Pedersen-Bjergaard, J., additional, Brincker, H., additional, Andersen, E., additional, Pedersen, M., additional, Nielsen, J. Boye, additional, Jensen, K. Bjørn, additional, Nissen, N. I., additional, Jensen, T. Skov, additional, Videbaek, Aa., additional, Jensen, M. Krogh, additional, and Walbom-Jørgensen, S., additional

Published
2009
Full Text
View/download PDF

31. S-phase induction by interleukin-6 followed by chemotherapy in patients with chronic lymphocytic leukemia and non-Hodgkin's lymphoma

Author

Brown, P D, Diamant, M, Jensen, P O, Geisler, C H, Mortensen, B T, Nissen, N I, Brown, P D, Diamant, M, Jensen, P O, Geisler, C H, Mortensen, B T, and Nissen, N I

Abstract

Interleukin-6 (IL-6) has in vitro demonstrated growth regulatory effects on tumor cells from patients with chronic lymphocytic leukemia (CLL) and lymphoma. The proliferation rate of these cells is usually very low and this is thought to be one of the reasons for the lack of a curative potential of cytostatic chemotherapy in CLL and low grade NHL. Recombinant human (rh) IL-6 might increase the in vivo proliferation rate leading to a higher sensitivity for chemotherapy. We tested this hypothesis by administering rhIL-6 to 9 CLL patients and 3 NHL patients in doses of 2.5 micrograms/kg, 5 micrograms/kg and 10 micrograms/kg s.c. daily for 5 days followed by CHOP chemotherapy on the last day of rhIL-6 injection. Six patients had two treatment cycles. The proportion of cells in S-phase was determined by the bromodeoxyuridine labeling index (LI). Three patients achieved a partial remission, one patient had progressive disease and the remaining patients demonstrated no change. Two patients, who received 10 micrograms/kg/day rhIL-6, demonstrated a significant increase in LI, one of these was first observed in the second treatment cycle. A significant decrease was seen in two patients receiving 2.5 micrograms/kg and 5 micrograms/kg respectively. Immunophenotypic assessment demonstrated that rhIL-6 increased the expression of CD20 in all CLL patients with a reversal after cessation of rhIL-6. We conclude that rhIL-6, in the dosage and schedule used in this study, did not increase the proportion of the cells in S-phase and that the growth stimulatory effects of rhIL-6 in CLL in vivo probably are insignificant. However, the role of rhIL-6 in CLL as inducer of increased CD20 expression prior to anti-CD20 antibody treatment remains to be determined.

Published
1999

32. S-phase induction by interleukin-6 followed by chemotherapy in patients with refractory multiple myeloma

Author

de Nully Brown, P, Jensen, P O, Diamant, M, Mortensen, B T, Hovgaard, D, Gimsing, P, Nissen, N I, de Nully Brown, P, Jensen, P O, Diamant, M, Mortensen, B T, Hovgaard, D, Gimsing, P, and Nissen, N I

Abstract

The plasma cell labeling index (PCLI) in patients with multiple myeloma (MM) is relatively low and this has been associated with the low rate of remission following chemotherapy. Interleukin-6 (IL-6) has been demonstrated to be a major growth factor of myeloma cells. In order to increase the S-phase proportion of myeloma cells, which might increase the sensitivity to chemotherapy, we gave rhIL-6 followed by chemotherapy to 15 myeloma patients with refractory disease. A total of 25 treatment cycles were administered since ten patients had two cycles. The rhIL-6 dose was 2.5 (n = 3), 5.0 (n = 6) and 10.0 microg/kg (n = 6) by subcutaneous injection once daily for 5 days and chemotherapy was administered on the last day of rhIL-6 injection. The effect of rhIL-6 treatment on labeling index (LI) was heterogeneous, but no statistically significant change was noted for this particular group as a whole. In two patients an increase (mean 7.7%) in LI of mononuclear bone marrow cells during the rhIL-6 treatment was demonstrated and in one patient a decrease of 2.8% was seen. Assessment of PCLI demonstrated an increase of 2.9% in one out of six patients and a decrease of 1.9% in one out of six patients. None of the 15 patients achieved remission according to standard criteria. During the rhIL-6 treatment, 14 of the 15 patients developed mild constitutional adverse events (AE) well known in patients treated with IL-6, and none of the AE in the subsequent chemotherapy phase were related to IL-6. In conclusion, our study demonstrated that rhIL-6 can be administered safely to patients with refractory MM, but the cell cycle recruitment approach was not sufficiently effective to be of clinical value.

Published
1998

33. Modulation of neutrophil and monocyte function by recombinant human granulocyte macrophage colony-stimulating factor in patients with lymphoma

Author

Kharazmi, A, Nielsen, H, Hovgaard, D, Borregaard, N, Nissen, N I, Kharazmi, A, Nielsen, H, Hovgaard, D, Borregaard, N, and Nissen, N I

Abstract

Udgivelsesdato: 1991-Apr, Granulocyte macrophage colony-stimulating factor (GM-CSF) has been shown to inhibit the chemotaxis and enhance the oxidative burst response of human neutrophils in vitro. The present study describes the effect of recombinant GM-CSF on the neutrophil and monocyte function in patients with lymphoma undergoing GM-CSF treatment. Patients with either Hodgkin's or non-Hodgkin's lymphoma were treated with various dosages (2-16 micrograms kg-1 body weight per day for 5 days) of rhGM-CSF by intravenous or subcutaneous route. Prior to and on day 5 of rhGM-CSF treatment, neutrophil and monocyte chemotaxis and chemiluminescence responses to f-Met-Leu-Phe, zymosan activated serum (ZAS) and opsonized zymosan (OZ) were determined. It was observed that chemotactic response of neutrophils to f-Met-Leu-Phe and ZAS was reduced, whereas the chemiluminescence response of both cell types to f-Met-Leu-Phe and zymosan was enhanced by up to 43-fold. rhGM-CSF treatment did not affect degranulation of the neutrophils as measured by release of vitamin B12 binding protein. Degree of modulation of neutrophil and monocyte function by rhGM-CSF was independent of rhGM-CSF dosages administered. These data suggest that phagocytic defence system may be enhanced by GM-CSF treatment and that this cytokine may be a useful therapeutic adjunct in compromised patients.

Published
1991

43. Lymphoblastic lymphoma: a clinicopathologic study of 95 patients.

Author

Nathwani, Bharat N., Diamond, Lawrence W., Winberg, Carl D., Kim, Hun, Bearman, Robert M., Glick, John H., Jones, Stephen E., Gams, Richard A., Nissen, Nis I., Rappaport, Henry, Nathwani, B N, Diamond, L W, Winberg, C D, Kim, H, Bearman, R M, Glick, J H, Jones, S E, Gams, R A, Nissen, N I, and Rappaport, H

Published
1981
Full Text
View/download PDF

46. Clinical trial of VP 16--213 (NSC 141540) I.V. twice weekly in advanced neoplastic disease: a study by the Cancer and Leukemia Group B.

Author

Nissen, Nis I., Pajak, Thomas F., Leone, Louis A., Bloomfield, Clara D., Kennedy, B. J., Ellison, Rose Ruth, Silver, Richard T., Weiss, Raymond B., Cuttner, Janet, Falkson, Geoffrey, Kung, Faith, Bergevin, Patrick R., Holland, James F., Nissen, N I, Pajak, T F, Leone, L A, Bloomfield, C D, Ellison, R R, Silver, R T, and Weiss, R B

Published
1980
Full Text
View/download PDF

48. Comparison of methyl-CCNU and CCNU in patients with advanced forms of Hodgkin's disease, lymphosarcoma nad reticulum cell sarcoma.

Author

Maurice, Pierre, Glidewell, Oliver, Jacquillat, Claude, Silver, Richart T., Carey, Robert, Pas, Andrew Ten, Cornell, Cornelius J., Burningham, Richard A., Nissen, Nis I., Holland, James F., Maurice, P, Glidewell, O, Jacquillat, C, Silver, R T, Carey, R, Pas, A T, Cornell, C J, Burningham, R A, Nissen, N I, and Holland, J F

Published
1978
Full Text
View/download PDF

49. Hodgkin disease in patients 60 years of age or older. Histologic and clinical features of advanced-stage disease. The Cancer and Leukemia Group B.

Author

Mir, Rabia, Anderson, James, Strauchen, James, Nissen, Nis I., Cooper, M. Robert, Rafla, Sameer, Canellos, George P., Bloomfield, Clara D., Gottlieb, Arlan J., Peterson, Bruce, Barcos, Maurice, Mir, R, Anderson, J, Strauchen, J, Nissen, N I, Cooper, M R, Rafla, S, Canellos, G P, Bloomfield, C D, and Gottlieb, A J

Published
1993
Full Text
View/download PDF

50. Tumor cell concentration and tumor burden in relation to histopathologic subtype and other prognostic factors in early stage Hodgkin's disease. The Danish National Hodgkin Study Group.

Author

Specht, Lena, Lauritzen, Anne Falensteen, Nordentoft, Axel M., Andersen, Per Kragh, Egelund, Bjarne, Hippe, Erik, Hou-Jensen, Klaus, Nissen, Nis I., Specht, L, Lauritzen, A F, Nordentoft, A M, Andersen, P K, Christensen, B E, Hippe, E, Hou-Jensen, K, and Nissen, N I

Published
1990
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results